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Summary
Objective: In this study we investigated the effect of interleukin-13 (IL-13), an anti-inflammatory
cytokine, for potential therapeutic use in osteoarthritis (OA).
Design: We examined the effect of IL-13 on the synthesis and expression of interleukin-1b (IL-1b),
tumor necrosis factor-a (TNF-a), IL-1 receptor antagonist (IL-1Ra) and stromelysin-1 on human OA
synovial membrane in ex vivo cultures. In addition, we explored the effect of IL-13 on both the IL-1
receptor (IL-1R) and TNF-receptor (TNF-R) systems on OA synovial fibroblasts. This included
determination of the levels of IL-1b and TNF-a receptor binding, IL-1Ra and TNF-soluble receptors 55
and 75 (TNF-sR55 and TNF-sR75).
Results: In OA synovial membrane treated with LPS, IL-13 inhibited the synthesis of IL-1b, TNF-a and
stromelysin-1, but increased IL-1Ra production. In addition, IL-13 reduced the level of IL-1b mRNA and
stimulated the level of IL-1Ra mRNA. In synovial fibroblasts, IL-13 decreased the level of IL-1 binding,
an effect related to the increased production of IL-1Ra. Although IL-13 had no effect on the TNF-R level,
this cytokine markedly decreased the shedding of TNF-R75.
Conclusion: These experiments suggest that IL-13 is potentially useful in the therapeutic treatment
of OA, as it could regulate the major pathological process of this disease by reducing the production
of proinflammatory cytokines and metalloproteases, and favoring the production of IL-1Ra.
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Introduction
Osteoarthritis (OA) is a disease characterized by
progressive cartilage destruction and secondary
inflammation of the synovial membrane [1]. Both
catabolic and antianabolic mechanisms are
believed to play a role in the pathophysiology of
this disease. Proinflammatory cytokines produced
in OA tissues, such as interleukin-1 (IL-1) and
tumor necrosis factor-a (TNF-a), may be instrumen-
tal in the disease process, since they both induce
synthesis of degradative enzymes such as metallo-
proteases (MMP) [1]. These cytokines have been
found in increased amounts in the joint tissues of
patients suffering from OA [1–6]. The predominant
role of IL-1b in the pathogenesis of this disease has
been suggested, both in human, by ex vivo
experiments [2], and in vivo, in an OA animal
model [7–9].
During the disease process, conditions may favor
proinflammatory cytokine inducibility, the in-
creased level of their receptors and/or the
inadequacy of inhibitory factors to block their
activity. Variations in the levels of cytokine
receptors and/or their soluble forms represent a
mechanism by which cellular responses to these
cytokines could be controlled. Another mechanism
is the production of a specific receptor antagonist.
Such a molecule has been identified only for the
IL-1 receptor (IL-1R), and named IL-1R antagonist
(IL-1Ra) [10]. In arthritic disorders, and more
particularly in OA, a relative deficit of IL-1Ra has
been suggested as a possible cause for an increased
level of IL-1 activity [2, 8, 9].
Another natural avenue to reducing proinflam-
matory cytokine production and/or activity
is through certain cytokines having anti-
inflammatory properties. Four such cytokines—
namely, transforming growth factor-b (TGF-b),
IL-4, IL-10 and IL-13—have been identified as able
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to modulate various inflammatory processes. Their
anti-inflammatory potential, however, appears to
depend greatly on the target cell. For example, IL-4
reduced IL-6 and TNF-a synthesis in blood
monocytes/macrophages, but not in the rheuma-
toid synovial fibroblasts [11, 12]. Similarly, IL-13
significantly inhibited lipopolysaccharide (LPS)-
induced TNF-a production by mononuclear cells
from peripheral blood, but not in cells from
inflamed synovial fluid [13].
In search of therapeutic agents capable of
regulating the inflammatory process, we investi-
gated the effect of an anti-inflammatory cytokine,
IL-13, on the human OA synovial membrane and
synovial fibroblasts. To date, transcripts for
human IL-13 have only been found in T-cells [14].
This human cytokine is an unglycosylated protein
of 132 amino acids, with a molecular size of 10 kDa
[15]. Although the discovery of IL-13 is recent,
many biological activities have already been
attributed to this cytokine. Of particular import-
ance, IL-13 inhibited the production of a wide
range of proinflammatory cytokines in monocytes/
macrophages, B cells, natural killer cells and
endothelial cells, while increasing IL-1Ra pro-
duction [15–18]; yet its effect on OA tissues and
cells has not been examined. A study of the effect
of this cytokine on OA tissue seems even more
relevant, as IL-13 has been identified in the
mononuclear cell infiltrate of the sublining layer of
OA synovium [19]. We therefore analyzed, using
OA synovial membrane explants and synovial
fibroblasts, the regulatory effect of IL-13 on two
major proinflammatory cytokine systems. More
specifically, we studied the effect of IL-13 on the
synthesis and expression of IL-1b, TNF-a, IL-1Ra,
and stromelysin-1, on human OA synovial mem-
brane. Furthermore, we looked at the effect of
IL-13 on both the IL-1R and TNF-R levels, as well
as on the production of IL-1Ra and TNF-soluble
receptors (TNF-sR) on OA synovial fibrblasts.
Materials and Methods
specimen selection
Synovial membranes were obtained from 16 OA
patients (mean age 70 2 8 years, 10F/6M)
undergoing total knee joint replacement. From the
X-rays, they were shown as being at stages III and
IV. All OA patients were evaluated by a certified
rheumatologist and diagnosed based on the
criteria developed by the ACR Diagnostic
Subcommittee for OA [20]. At the time of surgery,
they were treated with analgesics and/or
nonsteroidal anti-inflammatory drugs (NSAIDS).
None had intra-articular steroid injections within
3 months prior to surgery.
synovial membrane explant cultures
Each synovial membrane was aseptically
dissected from underlying fibrous and fatty tissues
and rinsed in cold saline solution as described [2].
The synovial explants of approximately 200 mg
each were randomly divided into groups. Tissues
were incubated in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco-BRL Canadian Life
Technologies, Burlington, ON, Canada)
containing 100 units/ml penicillin and 100 mg/ml
streptomycin (Gibco-BRL), in the presence or
absence of 1 mg/ml LPS (Escherichia coli serotype
055:B5; Sigma, St Louis, MO, U.S.A.), and with
increasing concentrations of human recombinant
IL-13 (rhIL-13) (R&D Systems, Minneapolis, MN,
U.S.A.). Two sets of experiments were carried out.
In the first set, synovial explants were incubated at
37°C for 72 h in a humidified 5% CO2/95% air
mixture, and determinations done on the culture
medium as described below. After each experiment,
the culture medium were frozen at −80°C before
biochemical measurements. In the second set of
experiments, synovial membrane explants were
incubated for 24 h in a humidified atmosphere,
and processed for total RNA extraction.
synovial fibroblast cultures
Synovial membranes were rinsed and dissected,
and cells released as previously described [21].
Sequential enzymatic digestion was performed
with 1 mg/ml pronase (Boehringer Mannheim,
Indianapolis, IN, U.S.A.) for 1 h, followed by 6 h
with 2 mg/ml collagenase (type IA, Sigma) at 37°C
in DMEM containing antibiotics and
supplemented with 10% heat inactivated fetal calf
serum (FCS, Hyclone, Logan, OH, U.S.A.). Before
seeding, the cells were incubated for 1 h at 37°C in
Primaria tissue culture flasks (Falcon (3824,
Lincoln Park, NJ, U.S.A.), allowing the adherence
of nonfibroblast cells possibly present in the
synovial preparation. In addition, flow cytometric
analysis was conducted to confirm that no
monocytes/macrophages were present in the
fibroblast preparations [21]. Synovial fibroblasts
were then seeded in high density in tissue culture
flasks, and cultured until confluence in DMEM,
supplemented with 10% FCS and antibiotics at
37°C in a humidified atmosphere of 5% CO2/95%
air. At the end of the incubation period, the cells
were again counted in representative wells and
data normalized to 5 × 105 cells/well. The cells were
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incubated in a fresh serum-free medium for
24 h before the experiment, with the
experiment conducted under serum-free medium.
Only primary culture or first passaged cells were
used.
binding assay
Receptor binding assays were performed for
IL-1b and TNF-a as previously described [21, 22].
Monolayer synovial fibroblast cultures were
washed in phosphate buffered saline (PBS) and
incubated with the binding buffer (PBS, 10 mm
HEPES, 0.5% gelatin, pH 7.4) for 4 h at 4°C
with [125I]-rhTNF-a (40 pm) (specific activity,
800–900 Ci/mmole; Dupont Canada Ltd.,
Mississauga, ON, Canada), or 3 h at 22°C with
[125I]-rhIL-1b (40 pm) (specific activity, 1450–
3200 Ci/mmole; Dupont Canada Ltd.), with or
without a 500-fold relative molar excess of
unlabeled human recombinant cytokine. After the
incubation period, the cells were washed by
immersion in ice-cold PBS, solubilized in
0.5% sodium dodecyl sulfate and radiolabel
counted. The number of cells was calculated
using parallel cultures in which synovial
fibroblasts were detached with trypsin-EDTA and
counted using the trypan blue method. Specific
binding was calculated as previously described
[21, 22].
northern blotting
Total RNA from synovial membrane explants
was extracted using the Trizol8 reagent
(Gibco-BRL) and processed according to the
manufacturer’s specifications. The extracted RNA
was quantitated spectrophotometrically. Five
micrograms (15 mg for TNF-a) of total RNA was
resolved on 1.2% agarose formaldehyde gels, and
transferred to nylon membranes (Hybond N,
Amersham Canada Ltd., Oakville, ON, Canada) in
10 mm sodium acetate buffer, pH 7.8, containing
20 mm Tris and 0.5 mm EDTA, overnight at
4°C. The human probes were as previously
described for IL-1b [23], TNF-a [23], IL-1Ra [24],
stromelysin-1 [25] and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) [23].
Prehybridization was carried out as described
[23], and detection performed with a luminescent
method using digoxigenin-11-uridyl triphosphate
(DIG-11-UTP) (Boehringer Mannheim Biochemica,
Mannheim, Germany) with Lumigen PPD
[4-methoxy-4-(3-phosphatephenyl) spiro-(1,2-
dioxetane-3,2'-adamantane)disodium salt] as
substrate for alkaline phosphatase conjugated to
anti-DIG antibody (Ab) Fab fragments, as
described in the Boehringer Mannheim user’s
guide. The membranes were then subjected to
autoradiography using Kodak XAR5 film (Eastman
Kodak Ltd., Rochester, NY, U.S.A.) at room
temperature. Autoradiography was subjected to
laser scanning densitometry (GS-300 Hoefer
Scientific Instruments, San Francisco, CA, U.S.A.)
for mRNA measurement, and the results calculated
as the relative expression normalized to the level
of GAPDH mRNA.
other analyses
IL-1b, TNF-a, IL-1Ra, stromelysin-1, type II
IL-1 soluble receptor (IL-1sR), TNF-sR55 and
TNF-sR75 proteins were all determined in the
culture medium using ELISA assay. All were
purchased from R&D Systems, except the
stromelysin-1 ELISA assay, which was purchased
from Amersham Canada Ltd. The sensitivity
for cell culture medium was 0.3 pg/ml for IL-1b,
4.4 pg/ml for TNF-a, 6.5 pg/ml for IL-1Ra,
3.75 ng/ml for stromelysin-1, 10 pg/ml for type II
IL-1sR, 1 pg/ml for TNF-sR55 and 0.5 pg/ml for
TNF-sR75. The reaction was measured on a
micro-ELISA Vmax photometer (Molecular
Devices Corp., Menlo Park, CA, U.S.A.). Data were
expressed as picograms or nanograms per
milligram tissue weight wet for synovial membrane
explant experiments, or per 5 × 105 cells when
synovial fibroblast cells were used.
Stromelysin activity was measured by the
method of Chavira et al [26] using azocoll as a
substrate, as previously described [27]. Total
enzyme activity was measured by the addition of
APMA (1 mm) to activate the latent form of the
enzyme. The chelator o-phenanthroline (5 mm) was
used as a blank. Enzyme activity was calculated in
units, in which one unit corresponds to hydrolysis
of 1 mg of substrate/hour at 37°C. The total
enzymatic activity was expressed in units per
milligram wet weight.
Results
effects of il-13 on cytokine and stromelysin in
oa synovial membranes
Synthesis
OA synovial membranes (N = 3 patients)
spontaneously produce IL-1b, IL-1Ra, and
stromelysin-1, but not TNF-a (Fig. 1). For the latter
enzyme and cytokines, LPS treatment increased
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Fig. 1. Human OA synovial membranes. Effect of IL-13 on the synthesis of (a) IL-1b, (b) TNF-a, (c) IL-1Ra,
(d) stromelysin-1, and (e) on the activity of stromelysin, in the absence or presence of 1 mg/ml LPS. Values are the
mean 2 s.e.m. of three independent patients.
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Fig. 2. Representative Northern blotting of IL-1b, stromelysin-1, IL-1Ra and GAPDH mRNA in OA synovial membranes
treated with IL-13 in the presence or absence of 1 mg/ml LPS.
their levels; about 51-fold for IL-1b [Fig. 1(a)], to
8 pg/mg tissue for TNF-a [Fig. 1(b)], 4.5-fold for
IL-1Ra [Fig. 1(c)] and 2.9-fold for stromelysin-1
[Fig. 1(d)]. As for the synthesis, stromelysin
activity also showed an increased level under LPS
[Fig. 1(e)].
For unstimulated and LPS-treated OA synovial
membrane, IL-13 suppressed the synthesis of
IL-1b, TNF-a and stromelysin-1 as well as
the stromelysin activity. Conversely, IL-13
induced a dose-dependent increase of the IL-1Ra
[Fig. 1(c)].
Gene Expression
Northern blot analysis (N = 2 patients) (Fig. 2,
Table I) revealed that, under basal conditions,
IL-1b expression was weak, while the level
increased with LPS treatment. The accumulation
of IL-1b mRNA induced by LPS was markedly
inhibited in a dose-dependent fashion by IL-13.
The level of expression of TNF-a under both
basal conditions and LPS treatment was below
the level of our detection methods despite the fact
that we loaded 15 mg/lane of total RNA and
Table I
Human osteoarthritic synovial membrane. Relative expression of mRNA normalized to GAPDH
Presence of LPS
(1 mg/ml)
Absence of LPS
rhIL-13
(ng/ml) 0 1 5 10 50 0 1 5 10 50
IL-1b 1.31* 1.11 0.40 0.48 0.19 0.06 0.03 ND† ND ND
Stromelysin-1 1.12 1.43 1.23 1.26 0.98 0.68 0.55 0.54 0.41 0.40
IL-1Ra 1.36 1.89 1.69 2.19 1.27 0.15 0.12 0.14 0.21 0.47
Values are the mean of two independent patients[
$NDnot detectable[
4000
0
25
(10 µg/ml)
[1
25
I]
-I
L
-1
β s
pe
ci
fi
c 
bi
n
di
n
g 
(c
pm
/5
 ×
 1
05
 c
el
ls
)
3000
2000
1000
(b)
101IgG1–
Mab IL-1Ra (µg/ml)
5000
0
25
(10 µg/ml)
[1
25
I]
-I
L
-1
β s
pe
ci
fi
c 
bi
n
di
n
g 
(c
pm
/5
 ×
 1
05
 c
el
ls
)
3000
2000
1000
101IgG1–
Mab IL-1Ra (µg/ml)
4000
Presence of IL-13 (50 ng/ml)
60
0
%
 I
n
h
ib
it
io
n
 o
ve
r 
co
n
tr
ol
30
20
10
(a)
IL-13 (ng/ml)
50
40
10050101
IL-1β Binding 600
0
pg
/5
 ×
 1
05
 c
el
ls
300
200
100
IL-13 (ng/ml)
500
400
IL-1Ra
1000 50101
Osteoarthritis and Cartilage Vol. 6 No. 1 45
maximized the duration of autoradiography (data
not shown).
The level of IL-1Ra mRNA was also low under
basal conditions, with a noticeable elevation
occurring upon treatment with LPS (Fig. 2,
Table I). In explants, and more particularly with
those treated with LPS, IL-13 induced an increase
in IL-1Ra mRNA.
In contrast to the protein activity level, no effect
by IL-13 was noted on the level of stromelysin-1
expression (Fig. 2, Table I) under both untreated
and LPS-treated conditions.
Fig. 3. Human OA synovial fibroblasts. Effect of IL-13 on (a) the inhibition of IL-1 binding and IL-1Ra level (N = 3
independent patients), (b) IL-1 binding level in the presence of a monoclonal antibody (mAb) against human IL-1Ra
or the IgG1 as control in the absence (N = 2 independent patients) or presence (N = 2 independent patients) of rhIL-13.
Values are the mean 2 s.e.m.
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effects of il-13 on il-1 and tnf-a receptor
systems in oa synovial firoblasts
To further investigate the role of IL-13 on IL-1
and TNF-a, we looked at its effects on the IL-1
and TNF-a specific receptors. This study was
performed on OA synovial fibroblasts, as these
cells appear central to the destruction processes in
OA [1, 6].
Effects of IL-13 on IL-1R
As illustrated in Fig. 3(a), the level of IL-1
binding (N = 3 patients) was substantially reduced
with IL-13 and occurred in a dose-dependent
manner. At 100 ng/ml, IL-13 induced a 40%
inhibition in the level of binding. The decrease in
[125I]-IL-1 binding may be the result of factors
capable of blocking IL-1 binding to its receptor site
(i.e., IL-1Ra) or forming an inactive complex with
IL-1 (i.e., release of the type II IL-1R). We therefore
examined the effect of IL-13 on the level of these
factors.
Results showed that, as for the OA synovial
membrane, IL-13 increased the production of
IL-1Ra by synovial fibroblasts (N = 3 patients)
which showed a dose-response, with an
approximate four-fold enhancement at the highest
IL-13 concentration (100 ng/ml) tested [Fig. 3(a)].
The level of type II IL-1sR was also determined.
Results showed that its level in the culture medium
with or without IL-13 was below the limit of
detection (data not illustrated).
In order to confirm that the increased
production of IL-1Ra was responsible for the effect
of IL-13 on IL-1b binding, further experiments
(N = 3 patients) were performed in which a
neutralizing IL-1Ra antibody (monoclonal Ab
( 10307.1, generously provided by R&D Systems)
was added at increasing concentrations (0, 1, 10,
25 mg/ml) [Fig. 3(b)]. IL-1 binding assay was
performed, as described in the Materials and
Methods section, on OA synovial fibroblasts. As
shown in Fig. 3(b), the addition of the IL-1Ra Ab
to the culture medium under basal conditions did
not affect the [125I]-IL-1 binding. When IL-13 was
added in conjunction with the IL-1Ra Ab (N = 3
patients), a decrease of the IL-1 binding was
noted with complete inhibition reached at a
concentration of 10 mg/ml IL-1Ra Ab. Experiments
performed with the isotype-matched nonimmune
IgG showed no effect on the binding; this was
found both in the presence and in the absence of
IL-13 [Fig. 3(b)].
Effects of IL-13 on TNF-a receptors
Further experiments were conducted in which
the TNF-a binding level was evaluated on OA
synovial fibroblasts (N = 3 patients) treated with
IL-13. Results, as represented in Fig. 4, revealed
that IL-13 did not affect the level of binding of
TNF-a to OA cells.
As the extracellular portion of each of the two
types of TNF-R could be released from the
Fig. 4. Human OA synovial fibroblasts. Effect of IL-13 on TNF-a binding and TNF-sR55 and TNF-sR75 levels. Values
are the mean 2 s.e.m. of three independent patients.
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membrane to form soluble receptors, their levels
were also determined. Data (Fig. 4) showed, as
previously described [28], that both TNF-R55 and
TNF-R75 are shed from OA synovial fibroblasts
with a greater amount of release for the TNF-R55.
IL-13 did not affect the level of TNF-sR55, but
induced a dose-dependent decrease for the
TNF-sR75 release (Fig. 4).
Discussion
Structural changes and cartilage destruction are
key events in the OA process. An imbalance
between the synthesis level of inflammatory and
anti-inflammatory factors in articular joint tissue
may contribute to the degradation of articular
cartilage. Therefore, controlling production of
some of these factors would be a major
achievement in the treatment of OA. In this
context, studying the effect of IL-13, a potent
anti-inflammatory cytokine was thought to be most
relevant. Our results highlight a further potential
usefulness for IL-13 in the treatment of OA, as it is
capable of inhibiting IL-1b, TNF-a and
stromelysin-1 synthesis and stromelysin activity on
OA synovial membrane, while simultaneously
increasing production of IL-1Ra. Moreover, IL-13
downregulates IL-1b while upregulating IL-1Ra
gene expression. Our study also showed that the
IL-13-stimulated-IL-1Ra level may decrease the IL-1
binding to its cognate receptor, thereby limiting its
biological activity.
In OA, proinflammatory cytokines, as well as
MMP, play a pivotal role in mediating
pathophysiological mechanisms, and contribute to
the evolution of the disease process [1]. IL-1b
demonstrated a predominant role in the
etiopathology of OA [2, 7–9], in contrast to
rheumatoid arthritis where TNF-a appears to play
a major role. In OA, the level of TNF-a in the
articular joint tissues was modest and variable,
and was found in a higher level in severely
inflamed synovial membrane [2, 4, 5, 29]. The
results of these previous studies are in accordance
with the findings of the present study. As these
proinflammatory cytokines function as networks,
the regulating effect of IL-13 at controlling the
expression and synthesis of these cytokines is
therefore critical to the outcome of this disease
process.
Results of our study showed that IL-13 exerts a
suppressive effect on the synthesis of IL-1b, TNF-a
and stromelysin-1, agreeing with previous reports
on mononuclear cells from peripheral blood
[13, 14]. Our data, however, differed from those
reported on macrophages that were isolated from
synovial fluid of arthritic patients, which did not
seem to respond to IL-13, at least in regard to
TNF-a [13]. One should note that, in synovial fluid,
the macrophages are already activated. However,
our results likely reflect that, in OA, we tested a
cell population different from the one found in the
synovial fluid. Indeed, in contrast to more
inflammatory arthritic diseases, in OA, the
synovial fibroblasts from the lining cell appear the
main cell type responsible for producing
proinflammatory cytokines and MMP, rather than
the infiltrate monocytes/macrophages.
As the action of one particular factor might
occur at various levels of cell metabolism, it
seemed important that we investigate the effect of
IL-13 on cytokine and MMP gene expression.
Results showed that the effect of IL-13 at inhibiting
IL-1b production was related to a decrease in gene
expression. No effect, however, was noted on the
stromelysin-1 mRNA level, indicating that in this
case, the IL-13 action may occur at translational or
post- translational levels or be indirect and related
to the inhibition of pro-inflammatory cytokines.
The latter is a likely possibility as additional
experi- ments revealed that the inhibition of
stromelysin-1 synthesis by IL-13 on synovial
membrane could be reversed (070%) by the
addition of either IL-1b or TNF-a (personal
observation).
As a cytokine can regulate the expression of
homologous or heterologous receptors, it appeared
most appropriate to explore the effect of IL-13 on
the IL-1b and TNF-a receptors of OA synovial
fibroblasts which participate actively in the
development of synovitis in this disease. In OA
synovial fibroblasts, IL-13 induced a decreased
level of IL-1 binding, but not of TNF-a binding.
Additional experiments showed that the effect of
IL-13 on reducing IL-1 binding level could be
related to the enhancement of the level of IL-1Ra
by these cells, but not as reported with
polymorphonuclear cells, to an increased release of
the type II IL-1R [30]. Although one cannot
completely exclude the latter possibility in the
synovial fibroblasts, if this process occurs, it
probably plays a minor role, as the level of the
soluble form of type II IL-R was under the assay
limit of detection, both in the presence and absence
of IL-13. The actual findings showing the effect of
IL-13 at reducing the IL-1 binding level by
increasing the IL-IRa level may or may not have
relevancy in situ in OA tissues. However, the
multiple effects of IL-13 on the IL-1 system, namely
increasing IL-1Ra at the same time that it reduces
the synthesis of IL-1, are certainly creating
conditions which are favorable for decreasing the
stimulation of OA cells by IL-1.
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While IL-13 had no effect on the number of
TNF-a binding sites, it was capable of inducing a
marked decrease in the shedding of the TNF-R75,
a process which might contribute to reducing the
response of these cells to stimulation by TNF-a.
Although the exact role of TNF-sR in the control
of TNF-a action remains controversial, some
studies indicate the possibility that TNF-sR75 is
involved in facilitating the binding of TNF-a to its
receptor and/or stabilizing its ligand [31, 32].
Therefore, the TNF-sR would function as a carrier
rather than an inhibitor of TNF-a. On the other
hand, the reduced shedding of TNF-sR75 could
have a detrimental effect if it was to act as a
scavenger to TNF-a, thus allowing for a greater
stimulation of cells by the cytokine. The reduction
in TNF-sR75 may have somewhat increased the
level of TNF-R75 at the cell surface. However,
since they do not mediate cell signaling [22], it is
therefore unlikely that IL-13 could have increased
the cell response to stimulation by TNF-a
throughout that mechanism.
In summary, this in vitro study provides useful
information on the effect of IL-13 on cellular
metabolism and on the potential use in the
therapeutic treatment of OA, as it could regulate
some of its major pathological processes by
reducing the production of proinflammatory
cytokines and MMP, and favoring the production
of IL-1Ra. Further studies will be needed to explore
the usefulness of this anti-inflammatory cytokine
in the context of the clinical treatment of this
disease.
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